Cited 34 times in
Adjunctive Cilostazol Versus Double-Dose Clopidogrel After Drug-Eluting Stent Implantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권혁문 | - |
dc.date.accessioned | 2018-11-20T11:46:44Z | - |
dc.date.available | 2018-11-20T11:46:44Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1936-8798 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/165658 | - |
dc.description.abstract | OBJECTIVES: This study sought to test the noninferiority of triple antiplatelet therapy (TAT) versus double-dose clopidogrel dual antiplatelet therapy (DDAT) in patients undergoing percutaneous coronary intervention (PCI). BACKGROUND: Antiplatelet regimen is an integral component of medical therapy after PCI. A 1-week duration of doubling the dose of clopidogrel was shown to improve outcome at 1 month compared with the conventional dose in patients with acute coronary syndrome undergoing PCI. Yet in Asia, the addition of cilostazol is used more commonly than DDAT in high-risk patients. METHODS: We randomly assigned 3,755 all-comers undergoing PCI to either TAT or DDAT, which was continued for 1 month, to test the noninferiority of TAT versus DDAT. The primary outcome was the cumulative incidence of net clinical outcome at 1 month post-PCI defined as the composite of cardiac death, nonfatal myocardial infarction, stent thrombosis, stroke, and PLATO (Platelet Inhibition and Patient Outcomes) major bleeding. RESULTS: TAT was noninferior to DDAT with respect to the primary outcome, which occurred in 1.2% and 1.4% of patients, respectively (-0.22% absolute difference, 0.34% 1-sided 97.5% confidence interval, p = 0.0007 for noninferiority; hazard ratio: 0.85; 95% confidence interval: 0.49 to 1.48; p = 0.558 for superiority). The individual risks of cardiac death, nonfatal myocardial infarction, stent thrombosis, stroke, and PLATO major bleeding did not differ significantly between the 2 groups. There were no significant between-group differences in the treatment effect with regard to the rate of the primary outcome. CONCLUSIONS: The adjunctive use of cilostazol was noninferior to doubling the dose of clopidogrel for 1 month in all-comers undergoing PCI with exclusively drug-eluting stents. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen [HOST-ASSURE]; NCT01267734). | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | JACC-CARDIOVASCULAR INTERVENTIONS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aspirin/administration & dosage | - |
dc.subject.MESH | Coronary Artery Disease/diagnosis | - |
dc.subject.MESH | Coronary Artery Disease/mortality | - |
dc.subject.MESH | Coronary Artery Disease/therapy* | - |
dc.subject.MESH | Coronary Thrombosis/etiology | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hemorrhage/chemically induced | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardial Infarction/etiology | - |
dc.subject.MESH | Percutaneous Coronary Intervention/adverse effects | - |
dc.subject.MESH | Percutaneous Coronary Intervention/instrumentation* | - |
dc.subject.MESH | Percutaneous Coronary Intervention/mortality | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/administration & dosage* | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/adverse effects | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Prosthesis Design | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Stroke/etiology | - |
dc.subject.MESH | Tetrazoles/administration & dosage* | - |
dc.subject.MESH | Tetrazoles/adverse effects | - |
dc.subject.MESH | Ticlopidine/administration & dosage | - |
dc.subject.MESH | Ticlopidine/adverse effects | - |
dc.subject.MESH | Ticlopidine/analogs & derivatives* | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Adjunctive Cilostazol Versus Double-Dose Clopidogrel After Drug-Eluting Stent Implantation | - |
dc.type | Article | - |
dc.contributor.college | 1. College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kyung Woo Park | - |
dc.contributor.googleauthor | Si-Hyuck Kang | - |
dc.contributor.googleauthor | Jin Joo Park | - |
dc.contributor.googleauthor | Han-Mo Yang | - |
dc.contributor.googleauthor | Hyun-Jae Kang | - |
dc.contributor.googleauthor | Bon-Kwon Koo | - |
dc.contributor.googleauthor | Byoung-Eun Park | - |
dc.contributor.googleauthor | Kwang Soo Cha | - |
dc.contributor.googleauthor | Jay Young Rhew | - |
dc.contributor.googleauthor | Hui-Kyoung Jeon | - |
dc.contributor.googleauthor | Eun Seok Shin | - |
dc.contributor.googleauthor | Ju Hyeon Oh | - |
dc.contributor.googleauthor | Myung-Ho Jeong | - |
dc.contributor.googleauthor | Sanghyun Kim | - |
dc.contributor.googleauthor | Kyung-KukHwang | - |
dc.contributor.googleauthor | Jung-Han Yoon | - |
dc.contributor.googleauthor | Sung Yun Lee | - |
dc.contributor.googleauthor | Tae-Ho Park | - |
dc.contributor.googleauthor | Keon Woong Moon | - |
dc.contributor.googleauthor | Hyuck-Moon Kwon | - |
dc.contributor.googleauthor | In-Ho Chae | - |
dc.contributor.googleauthor | Hyo-Soo Kim | - |
dc.identifier.doi | 10.1016/j.jcin.2013.04.022 | - |
dc.contributor.localId | A00260 | - |
dc.relation.journalcode | J01193 | - |
dc.identifier.eissn | 1876-7605 | - |
dc.identifier.pmid | 24050860 | - |
dc.subject.keyword | ACS | - |
dc.subject.keyword | CI | - |
dc.subject.keyword | DDAT | - |
dc.subject.keyword | HOPR | - |
dc.subject.keyword | MI | - |
dc.subject.keyword | OPR | - |
dc.subject.keyword | PCI | - |
dc.subject.keyword | TAT | - |
dc.subject.keyword | acute coronary syndromes | - |
dc.subject.keyword | antiplatelet therapy | - |
dc.subject.keyword | cliostazol | - |
dc.subject.keyword | clopidogrel | - |
dc.subject.keyword | confidence interval | - |
dc.subject.keyword | double-dose clopidogrel dual antiplatelet therapy | - |
dc.subject.keyword | high on-treatment platelet reactivity | - |
dc.subject.keyword | myocardial infarction | - |
dc.subject.keyword | on-treatment platelet reactivity | - |
dc.subject.keyword | percutaneous coronary intervention | - |
dc.subject.keyword | randomized controlled trial | - |
dc.subject.keyword | triple antiplatelet therapy | - |
dc.contributor.alternativeName | Kwon, Hyuck Moon | - |
dc.contributor.affiliatedAuthor | 권혁문 | - |
dc.citation.volume | 6 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 932 | - |
dc.citation.endPage | 942 | - |
dc.identifier.bibliographicCitation | JACC-CARDIOVASCULAR INTERVENTIONS, Vol.6(9) : 932-942, 2013 | - |
dc.identifier.rimsid | 60290 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.